CBMG

Cellular Biomedicine Group Inc

A clinical-stage biopharmaceutical company that engineers a patient's own immune cells into living therapies to fight cancer. Its main products are CAR-T cell therapies—such as treatments that target proteins like CD19 and CD20 on blood cancers—plus T-cell receptor and tumor-infiltrating lymphocyte therapies for solid tumors. Founded in 2009 and one of the first Chinese biotech firms to list publicly in the United States, it rebranded as AbelZeta Pharma in 2023 after spinning off its stem-cell business. The name blends "Abel," chosen to signify humility and conviction, with "Zeta," the Greek letter for a part of the T-cell receptor that lies at the heart of its research.